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Aim Dilated cardiomyopathy (DCM) has a variety of causes, and no useful approach to predict left ventricular (LV)
remodelling and long-term outcome has yet been established. Myocardial tenascin-C (TNC) is known to appear
under pathological conditions, possibly to regulate cardiac remodelling. The aim of this study was to clarify the
significance of myocardial TNC expression in LV remodelling and the long-term outcome in DCM.
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Methods
and results
One hundred and twenty-three consecutive DCM patients who underwent endomyocardial biopsy for initial diagnosis
were studied. Expression of TNC in biopsy sections was analysed immunohistochemically to quantify the ratio of the
TNC-positive area to the whole myocardial tissue area (TNC area). Clinical parameters associated with TNC area
were investigated. The patients were divided into two groups based on receiver operating characteristic analysis of
TNC area to predict death: high TNC group with TNC area ≥2.3% (22 patients) and low TNC group with TNC
area <2.3% (101 patients). High TNC was associated with diabetes mellitus. Comparing echocardiographic findings
between before and 9months after endomyocardial biopsy, the low TNC group was associated with decreased LV
end-diastolic diameter and increased LV ejection fraction, whereas the high TNC group was not. Survival analysis
revealed a worse outcome in the high TNC group than in the low TNC group (P< 0.001). Multivariable Cox
regression analysis revealed that TNC area was independently associated with poor outcome (HR= 1.347, P= 0.032).
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Conclusions Increased myocardial TNC expression was associated with worse LV remodeling and long-term outcome in DCM.
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Introduction
Dilated cardiomyopathy (DCM) is characterized by ventricular
enlargement and impaired contractile function. The prognosis
of DCM remains unfavourable, with a high incidence of sudden
cardiac death and heart failure, and an estimated overall 1-year
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. mortality rate between 10% and 30%, and some patients with DCM
require heart transplantation.1,2 Because of the widely diverse
background characteristics of patients with DCM, the outcome
of these patients is almost unpredictable, even with a variety
of examinations, including blood tests, electrocardiography, chest
X-ray, echocardiography, scintigraphy, and cardiac catheterization.
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Therefore, new prognostic indicators to stratify the future risk of
DCM are strongly awaited.
Tenascin-C (TNC), a large hexametric glycoprotein, is known
to appear in the extracellular matrix specifically following tis-
sue injury or tumour formation where the particular organ is
undergoing remodelling.3 As regards the cardiac system, TNC
is synthesized and expressed under pathological conditions in
myocardial infarction, acute myocarditis, and DCM, suggesting a
potential impact on the progression of cardiovascular diseases.4,5
For example, TNC exacerbated heart failure by acceleration of
left ventricular (LV) remodelling and an increase in fibrosis after
myocardial infarction in a mouse model.6 However, the effect of
myocardial TNC expression with LV remodelling and long-term
outcome in DCM has not yet been fully investigated. Similarly, the
clinical background in which expression of TNC is increased in
the myocardium has not been elucidated, although TNC is known
to be synthesized by interstitial fibroblasts under inflammatory
stimulation.3
The objective of this study was to investigate the associa-
tion of myocardial TNC expression with LV remodelling and the
long-term outcome. In addition, we examined the clinical fac-
tors of patients predisposed to increased tissue TNC expression
in DCM.
Methods
Study population
Patients who were diagnosed with DCM in our hospital between 2005
and 2008 with impaired contractile function with left ventricular ejec-
tion fraction (LVEF) <40% and left ventricular end-diastolic diameter
(LVEDD) >55mm were screened for the study. All patients underwent
clinical evaluation, physical examination, 12-lead electrocardiography,
laboratory tests, echocardiography, and cardiac catheterization,
including coronary angiography and right ventricular (RV) septal
endomyocardial biopsy for initial diagnosis. All patients underwent RV
endomyocardial biopsy according to the indications in the American
Heart Association, American College of Cardiology, and European
Society of Cardiology scientific statement, mainly to exclude myocardi-
tis or secondary cardiomyopathy.7 Endomyocardial biopsy was
performed after obtaining written informed consent with information
about the procedure and the risk of endomyocardial biopsy. Because
medical therapy was optimized during hospitalization in most of the
patients, information about the use of medication for heart failure
such as 𝛽-blockers, angiotensin converting enzyme (ACE)-inhibitors or
angiotensin receptor blockers (ARBs), and loop diuretics was collected
separately on admission and at discharge. Patients with hypertrophic
cardiomyopathy, ischaemic cardiomyopathy, valvular heart disease,
relevant (LV) hypertrophy suggested to be caused by hypertensive
heart disease, or secondary cardiomyopathy such as that caused by
sarcoidosis or amyloidosis were excluded. Patients with a history of
uncontrolled hypertension or LV assist device implantation were also
excluded.
Study protocol
Information about the patients’ baseline characteristics, such as age,
gender, body mass index, presenting symptoms, blood pressure, heart ..
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.. rate, previous comorbid conditions, and laboratory data (e.g. BNP,
haemoglobin, serum creatinine), were collected from their medical
records. Data on medication were collected both on admission and
at discharge. Sections from stored paraffin-embedded RV septal tissue
were stained with a specific antibody to TNC to evaluate TNC expres-
sion in the myocardium. Echocardiography was performed before and
at 9months after RV biopsy. Survival data were also collected in order
to perform survival analysis. This study was performed according to
the Helsinki Declaration and was approved by the ethics committee of
our institution.
Heart failure risk score
To evaluate heart failure severity, we used heart failure risk score
accessible by the website http://www.heartfailurerisk.org.8 This is the
generalizable easily used integer risk score for mortality in patients
with heart failure, including 13 independent predictors: age, LVEF,
New York Heart Association (NYHA) class, serum creatinine, dia-
betes mellitus, 𝛽-blocker, systolic blood pressure, body mass index,
time since diagnosis, current smoker, chronic obstructive pulmonary
disease, male gender, and ACE inhibitor or ARB.
Echocardiography
Echocardiographic parameters were measured according to the rec-
ommendations of the American Society of Echocardiography.9 The
LVEDD, left ventricular end-systolic diameter (LVESD), thickness of the
interventricular septum and posterior ventricular wall, and left atrial
diameter were obtained from M-mode or two-dimensional images
of parasternal long axis views. Left ventricular end-diastolic diameter
index (LVEDDI) was calculated as LVEDD divided by body surface area.
LVEF was calculated by the Teichholz formula.10 Mitral regurgitation
was semiquantitatively graded from 1 to 4 considering the regurgitant
area at colour Doppler imaging. Peak early (E), late (A) diastolic trans-
mitral filling velocities, and deceleration time of E were measured, and
E/A ratio was calculated. Restrictive filling pattern was defined as the
E-wave deceleration time of <115ms.11
Cardiac catheterization
Patients underwent diagnostic cardiac catheterization. Coronary
angiography was performed to exclude ischaemic heart disease, and
right heart catheterization was performed to obtain haemodynamic
data including cardiac output, pulmonary capillary wedge pressure
(PCWP), and pulmonary artery pressure (PA). Endomyocardial biopsy
was also performed, and three to five pieces of ventricular tissue were
obtained from different locations in the septal wall of the right ventricle
using disposable biopsy forceps (Technowood Co., Ltd., Tokyo, Japan).
The specimens were immediately fixed with 10% buffered formalin,
embedded in paraffin, serially sectioned and stained with haematoxylin
and eosin staining. Masson’s trichrome staining was also performed to
detect fibrosis.
Immunohistochemistry for tenascin-C
Immunohistochemical staining on formalin-fixed paraffin-embedded
sections was performed using an autostainer Leica Bond-III (Leica
Biosystems, Melbourne, Australia) according to the manufac-
turer’s protocol. For antigen retrieval, slides were treated with
Enzyme 1 using a Bond Enzyme Pretreatment Kit (AR9551;
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Table 1 Patient characteristics by tenascin-C (TNC) area
Total, n= 123 High TNC, n= 22 Low TNC, n=101 P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographic characteristics
Age, years 50.4±14.5 45.9±16.9 51.4±13.9 0.186
Male 103 (84) 20 (91) 83 (82) 0.317
Body mass index, kg/m2 23.8± 4.3 23.2± 4.8 23.9± 4.2 0.488
Current smoker 34 (28) 4 (18) 34 (34) 0.156
NYHA class III/VI 41 (33) 10 (46) 31 (31) 0.185
Duration of heart failure, months 21.6± 51.4 51.3± 92.2 15.1± 34.6 0.026
Systolic blood pressure, mmHg 116± 23 110± 22 117± 23 0.200
Diastolic blood pressure, mmHg 69±12 67±11 69±12 0.706
Heart rate, beats/min 74±15 75±17 73±14 0.639
Hypertension 49 (40) 9 (41) 40 (40) 0.910
Diabetes mellitus 19 (15) 8 (36) 11 (11) 0.003
Dyslipidaemia 63 (51) 11 (50) 52 (52) 0.900
Atrial fibrillation 28 (23) 8 (36) 20 (20) 0.095
Left bundle branch block 16 (13) 4 (18) 12 (12) 0.439
ICD/BiV-ICD 8 (7) 3 (14) 5 (5) 0.707
Laboratory findings
Log BNP 2.26± 0.59 2.59± 0.38 2.19± 0.61 0.003
HbA1c, % 6.1± 0.9 6.2±1.0 6.0± 0.9 0.455
Haemoglobin, g/dl 14.3±1.9 14.2±1.2 14.3± 2.0 0.905
eGFR, mL/min.1.73m2 56.2± 20.9 55.2±19.9 56.4± 21.2 0.448
Serum sodium, mEq/L 138± 4 139± 3 139± 5 0.577
Medication on admission
𝛽-blocker 53 (43) 12 (55) 41 (41) 0.233
ACE inhibitor/ARB 77 (63) 16 (73) 61 (60) 0.281
Loop diuretic 81 (66) 18 (82) 63 (62) 0.083
Aldosterone inhibitor 50 (41) 13 (59) 37 (37) 0.057
Sulphonylurea 1(1) 0 (0) 1 (1) 0.641
Glinide 2 (2) 0 (0) 2 (2) 0.507
Insulin 2 (2) 1 (5) 1 (1) 0.234
Medication at discharge
𝛽-blocker 109 (89) 20 (91) 89 (88) 0.710
ACE inhibitor/ARB 98 (80) 21 (95) 77 (76) 0.043
Loop diuretic 78 (63) 19 (86) 59 (58) 0.014
Aldosterone inhibitor 62 (50) 15 (68) 47 (47) 0.067
Sulphonylurea 1 (1) 0 (0) 1 (1) 0.641
Glinide 2 (2) 1 (5) 1 (1) 0.234
Insulin 3 (2) 1 (5) 2 (2) 0.481
Echocardiographic findings
LVEDD, mm 68.5± 8.4 70.2± 8.0 68.1± 8.5 0.179
LVESD, mm 59.4± 8.9 60.9± 9.3 59.1± 8.8 0.411
LVEF, % 25.2± 8.0 25.7± 8.0 25.1± 8.1 0.932
LAD, mm 46.1± 7.1 47.6± 6.7 45.8± 7.2 0.213
RVD, mm 29.9± 6.1 32.0± 6.9 29.4± 5.9 0.102
Mitral regurgitation 1.3± 0.9 1.3± 0.8 1.2± 0.9 0.579
Restrictive filling pattern 23 (19) 8 (36) 15 (15) 0.020
Haemodynamic data
Mean PCWP, mmHg 12.1± 8.1 16.8± 8.6 11.1± 7.6 0.003
Mean PA, mmHg 20.0±10.1 25.9±10.1 18.7± 9.6 <0.001
Cardiac index, L/min.m2 2.4± 0.6 2.2± 0.6 2.4± 0.6 0.171
Heart failure risk score 19.8± 6.6 22.0± 7.0 19.4± 6.4 0.116
Collagen area, % 14.4± 7.7 20.5±10.5 13.1± 6.2 0.001
TNC, tenascin-C; NYHA, New York Heart Association; ICD, implantable cardioverter defibrillator; BiV-ICD, biventricular implantable cardioverter defibrillator; BNP, brain
natriuretic peptide; HbA1C, haemoglobin A1c; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; LVEDD,
left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; RVD, right ventricular
diameter; PCWP, pulmonary capillary wedge pressure; PA, pulmonary artery pressure.
Values are mean± SD or n (%)
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Representative microscopic images of biopsy specimens. (A) Collagen area (blue-stained area) stained with Masson’s trichrome was
measured as 30.5%. (B) Tenascin-C (TNC)-positive area in immunohistochemical staining for TNC was measured as 9.9%, falling in the high
TNC group. (C) TNC-positive area in immunohistochemical staining for TNC was measured as 0.5%, falling in the low TNC group.
Figure 2 Distribution of tenascin-C area. Mean tenascin-C area was 1.4± 2.0%, ranging from 0.1 to 10.4% with more than 80% of all patients
showing a tenascin-C area <2.0%.
Leica Biosystems, Newcastle-upon-Tyne, UK) for 5min at 37 ∘C.
Slides were then incubated for 15min at room temperature
with a commercially available mouse monoclonal antibody for
TNC (4F10TT, 1:1000 dilution; Immuno-Biological Laboratory
Co., Ltd., Gunma, Japan), which recognizes epidermal growth
factor (EGF)-like domain, constitutive sites of the TNC molecules.12
Antibody detection and counterstaining with haematoxylin were
performed using Bond Polymer Refine Detection Kit (DS9800; Leica
Biosystems). Non-immunized mouse IgG (X0931, 1:1000 dilution;
Dako, Glostrup, Denmark) was substituted as a negative control for
the primary antibody against TNC to exclude possible false-positive
responses from the secondary antibody or from non-specific binding
of IgG. ..
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.. Analyses of myocardial collagen
accumulation and tenascin-C expression
Myocardial collagen accumulation and TNC expression were semi-
quantitatively measured in a blinded manner. Photomicrographs were
taken in five different randomly-selected high-power fields in the
low-magnification whole view of three to five pieces obtained by
endomyocardial biopsy. Images were analysed with National Institutes
of Health imaging software. The ratio of total blue-stained area without
endocardium and blood vessels to whole myocardial area in Masson’s
trichrome-stained sections was calculated. The average value was taken
to represent collagen accumulation and defined as the collagen area.
Similarly, the TNC area was expressed as the average of the ratio of
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Correlation between tenascin-C area and collagen area. Tenascin-C area was positively correlated with collagen area (r= 0.329,
P< 0.001).
TNC-positive area to the whole myocardial area in immunohistochem-
ically stained sections.
Statistical analysis
Data were analysed using the Statistical Package for Social Sciences
version 21.0 (SPSS Inc.; Chicago, IL, USA). All quantitative data were
expressed as mean± SD. The statistical significance of differences was
analysed using unpaired Student’s t-test for parametric continuous
variables, the Mann–Whitney U-test for non-parametric continuous
variables, and paired t-test to compare echocardiographic parame-
ters at baseline and follow-up. Categorical variables were compared
using Fisher’s exact test. Pearson’s correlation analysis was performed
to estimate correlations between TNC area and fibrosis area. The
receiver operating characteristic curve was constructed to deter-
mine the cut-off values. For survival analysis, the outcome of inter-
est was death, and other patients were censored at the time of LV
assist device implantation or heart transplantation, or at the day of
last follow-up. Event-free survival curves were constructed using the
Kaplan–Meier method, and the statistical significance of differences
between curves was assessed using the log-rank test. Cox propor-
tional hazard analysis was performed with 22 clinical variables that
are generally recognized parameters influencing heart failure prognosis
[age, body mass index, current smoker, NYHA class III or IV, duration
of heart failure, heart rate, systolic blood pressure, diabetes melli-
tus, implantable cardioverter defibrillator (ICD) or biventricular ICD,
logBNP, haemoglobin, estimated glomerular filtration rate, 𝛽-blocker
at discharge, ACE inhibitor or ARB at discharge, aldosterone inhibitor .
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.. at discharge, loop diuretic at discharge, LVEDDI, LVEF, mitral regurgi-
tation, restrictive filling pattern, heart failure risk score, fibrosis area]
and TNC area, and variables achieving P< 0.05 on univariable analysis
were then tested in multivariable Cox analysis to determine which ones
were significantly associated with death.8 Univariable linear regression
analysis for TNC area was performed using all variables in the baseline
characteristics, and then multivariable linear regression analysis was
performed using the variables achieving P< 0.05 on univariable linear
regression analysis to determine the factors associated with TNC area.
Values of P< 0.05 were considered statistically significant.
Results
Patient clinical characteristics
A total of 138 consecutive patients were finally diagnosed with
DCM, and of these, 123 patients with complete data collection
were included in the study. On admission, 43% and 63% of patients
were receiving 𝛽-blockers and ACE inhibitors/ARBs respectively,
but, at discharge, most of the patients were receiving these key
medications for heart failure, suggesting that medications were
optimized during hospitalization (Table 1). During the follow-up
period of 66± 35months, nine patients (7.3%) died and eight
patients (6.5%) underwent LV assist device implantation. No
patient underwent heart transplantation before LV assist device
implantation.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Receiver operating characteristic analysis of
tenascin-C area to predict death. The optimal cut-off value
of tenascin-C area to predict death in patients with dilated
cardiomyopathy was determined to be 2.3% based on the
receiver operating characteristic curve [sensitivity= 0.600, speci-
ficity= 0.858; area under the curve (AUC)= 0.773, P= 0.004] in
these study subjects.
Myocardial collagen area and myocardial
tenascin-C expression
A representative image of a Masson’s trichrome-stained section
is shown in Figure 1A (collagen area 30.5%). Collagen area ranged
from 0.4 to 44.9% (mean 14.4± 7.7%). Representative images
of TNC-stained histological sections with high (Figure 1B, TNC
area 9.9%) and low TNC (Figure 1C, TNC area 0.5%) expression
are also shown. The distribution of TNC area is depicted in
Figure 2. TNC area ranged from 0.1–10.4% (mean 1.4± 2.0%),
with more than 80% of all patients having TNC area ≤2%. The
TNC area was positively correlated with collagen area (r= 0.329,
p< 0.001; Figure 3). Based on receiver operating characteristic
analysis, the optimal cut-off value of TNC area to predict all-cause
death in patients with DCM was determined to be 2.3% (sensi-
tivity= 0.600, specificity= 0.858, area under the curve= 0.773,
P= 0.004; Figure 4) in these study subjects. We divided the patients
into two groups using this cut-off value; (i) high TNC group with
TNC area ≥2.3% (n= 22, 18%), and (ii) low TNC group with TNC
area <2.3% (n= 101, 82%).
Patient characteristics and tenascin-C
expression
Baseline characteristics were compared between the two groups
(Table 1). Higher TNC expression was associated with longer
duration of heart failure, higher incidence of diabetes mellitus
and discharge, a loop diuretic at discharge and an ACE inhibitor ..
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Figure 5 Kaplan–Meier curves for all-cause mortality.
Event-free survival was calculated for the high tenascin-C (TNC)
group (n= 22) and low TNC group (n=101) by Kaplan–Meier
method. Survival rate was significantly decreased in the high
TNC group compared with the low TNC group.
or ARB at discharge. Mean PCWP, mean PA, plasma BNP level
on admission, and collagen area in the high TNC group were
higher than those in the low TNC group. However, baseline NYHA
class, LV dimensions, LVEF, and heart failure risk score were not
significantly different between the groups.
Association of tenascin-C expression
with outcome
Kaplan–Meier survival curves demonstrated that the high TNC
group had a poorer outcome than the low TNC group (P< 0.001;
Figure 5). Univariable and multivariable Cox regression analyses
were performed to determine predictive factors for death. Systolic
blood pressure, diabetes mellitus, ICD or biventricular ICD, log
BNP, collagen area, and TNC area with a P-value <0.05 were
selected by univariable analysis. Among these, multivariable analysis
revealed that TNC area (hazard ratio=1.347, P= 0.032) was an
independent predictor of death (Table 2).
Left ventricular remodelling
One patient died and two others had an LV assist device implanted
before follow-up echocardiography. Follow-up echocardiographic
data were unavailable in 27 patients. A total of 94 patients (15
patients in the high TNC group and 79 patients in low TNC group)
underwent follow-up echocardiography performed 9± 4months
after the diagnosis of DCM. We found that LVEDD, LVESD
and LAD were significantly decreased (P< 0.001, P< 0.001, and
P< 0.001, respectively), and LVEF and deceleration time were
significantly increased (P< 0.001 and P< 0.001, respectively) at
follow-up compared with baseline in the low TNC group, while
these values did not differ between baseline and follow-up in the
high TNC group (Table 3). To compare LV remodelling between the
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Univariable and multivariable Cox regression analysis for death
Univariable Multivariable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95%CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 0.990 (0.948–1.033) 0.635 – –
Body mass index 1.067 (0.937–1.215) 0.329 – –
Current smoker 0.401 (0.085–1.889) 0.248 – –
NYHA class III/IV 0.923 (0.238–3.577) 0.908 – –
Duration of heart failure 1.008 (1.000–1.016) 0.063 – –
Heart rate 0.987 (0.944–1.032) 0.566 – –
Systolic blood pressure 0.955 (0.918–0.993) 0.020 0.981 (0.941–1.023) 0.367
Diabetes mellitus 5.298 (1.534–18.302) 0.008 4.323 (0.652–28.673) 0.129
ICD/BiV-ICD 15.115 (2.912–78.457) 0.001 7.801 (0.287–212.335) 0.223
Log BNP 6.728 (1.725–26.242) 0.006 6.661 (0.668–66.395) 0.106
Haemoglobin 0.904 (0.649–1.259) 0.904 – –
eGFR 0.999 (0.967–1.032) 0.941 – –
𝛽-blocker at discharge 0.446 (0.095–2.104) 0.308 – –
ACE inhibitor/ARB at discharge 0.558 (0.144–2.161) 0.398 – –
Aldosterone inhibitor at discharge 1.363 (0.384–4.838) 0.631 – –
Loop diuretics at discharge 1.783 (0.370–8.585) 0.471 – –
LVEDDI 0.986 (0.880–1.104) 0.802 – –
LVEF 1.028 (0.953–1.109) 0.473 – –
Mitral regurgitation 1.770 (0.841–3.723) 0.132 – –
Restrictive filling pattern 1.121 (0.233–5.400) 0.886 – –
Heart failure risk score 0.986 (0.908–1.103) 0.986 – –
Collagen area 1.089 (1.007–1.178) 0.032 1.016 (0.894–1.154) 0.808
Tenascin-C area 1.502 (1.243–1.814) <0.001 1.347 (1.026–1.768) 0.032
HR, hazard ratio; CI, confidence interval; BiV-ICD, biventricular implantable cardioverter defibrillator; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration
rate; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; LVEDDI, left ventricular end-diastolic diameter index; LVEF, left ventricular ejection fraction.
Table 3 Echocardiographic parameters at baseline and follow-up
High TNC (n= 15) Low TNC (n= 79)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline Follow-up P-value Baseline Follow-up P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LVEDD, mm 69.5± 8.6 64.7± 8.3 0.161 68.6± 9.2 53.4±10.6 <0.001
LVESD, mm 59.9± 9.6 54.4± 8.4 0.174 59.7± 9.5 46.6±12.6 <0.001
IVST, mm 8.8± 2.8 8.7± 2.7 0.928 8.7± 2.2 9.2± 2.1 0.094
PWT, mm 9.1± 2.2 8.8±1.3 0.928 9.1± 2.1 9.2± 2.0 0.695
LVEF, % 26.6± 8.2 29.8± 8.2 0.285 24.8± 8.2 39.8±13.4 <0.001
RVD, mm 32.5± 7.3 31.2± 6.6 0.780 29.5± 5.8 28.6± 5.0 0.290
E, cm/s 82.7± 29.3 68.2± 22.2 0.183 70.1± 28.6 63.8± 22.9 0.095
E/A 2.1± 1.0 1.1± 0.7 0.229 1.1± 0.6 1.0± 0.6 0.840
DcT, ms 145± 70 177± 61 0.139 169± 56 207± 56 <0.001
LAD, mm 49.3± 6.6 44.8± 11.5 0.134 46.4± 7.1 41.7± 7.9 <0.001
TNC, tenascin-C; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVST, interventricular septum thickness; PWT, posterior left
ventricular wall thickness; LVEF, left ventricular ejection fraction; RVD, right ventricular diameter; E, peak early diastolic transmitral filling velocity; E/A, peak early diastolic
transmitral filling velocity/peak late transmitral filling velocity ratio; Dct, deceleration time; LAD, left atrial diameter.
Values are mean± SD.
high and low TNC groups, we evaluated the changes in echocardio-
graphic parameters from baseline to follow-up. Changes in LVEDD
(P= 0.041) and LVESD (P= 0.010) were significantly smaller in the
low TNC group, and change in LVEF (P= 0.003) was greater in the
low TNC group compared with the high TNC group, suggesting
that LV reverse remodelling was less prone to be induced during
the follow-up period in the high TNC group (Figure 6). ..
..
..
..
..
..
..
..
..
.. Determinants of tenascin-C area
Univariable and multivariable linear regression analysis were per-
formed to determine the background characteristics associated
with the high TNC area. All variables in the baseline patient
characteristics were selected for univariable analysis. Among
these variables, diabetes mellitus, ICD or biventricular ICD, mean
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 6 Changes in left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), and left ventricular
ejection fraction (LVEF) in high tenascin-C (TNC) group and low TNC group. The bottom and top of the box are the first and third quartiles,
and the band inside the box is the median. The ends of the whiskers denote 1.5 interquartile range of the lower and upper quartiles. The circles
represent outliers. Changes in LVEDD (−9.2± 8.6mm vs. –4.9± 7.2mm) and LVESD (−13.0±10.4mm vs. –5.5± 8.5mm) were significantly
smaller in the low TNC group compared with the high TNC group. The change in LVEF was significantly smaller in the high TNC group
(3.2± 10.8% vs. 15.0±12.6%). These data suggest that the high TNC group was associated with lower occurrence of reverse remodelling in
patients with dilated cardiomyopathy.
PCWP, and mean PA were shown to be independent determinants
of high TNC area by multivariable analysis (Table 4).
Discussion
In the present study, we found that myocardial TNC expression,
immunohistochemically stained and analysed semiquantitatively in
RV biopsy samples, was a useful predictor of LV remodelling and
long-term outcome.
The outcome of DCM varies greatly among individual cases and
is closely associated with the degree of LV remodelling and whether
cardiac function is improved by conventional therapy, including
𝛽-blockers and ACE-inhibitors.13,14 Left ventricular remodelling
is affected by various kinds of neurohumoral and local factors
such as the renin–angiotensin–aldosterone system, the adrener-
gic nervous system, increased oxidative stress, proinflammatory
cytokines, and endothelin.13–17 However, the precise mechanisms
that cause LV remodelling are still unclear.
Ventricular extracellular matrix proteins, which maintain cardiac
structure and architecture in combination with myocytes, play
a central role in LV remodelling in DCM.18 Recently, several
studies have shown that TNC, one of the extracellular matrix
component proteins, is expressed in association with several
cardiovascular diseases.19,20 This large glycoprotein (>300 kDa) is
expressed only during the development of the embryonic heart
and not in the normal adult heart.21 However, when exposed
to mechanical or ischaemic stress, it reappears in the heart. For
example, TNC is expressed after myocardial infarction, in acute or
chronic myocarditis, and in DCM in response to tissue injury and
inflammation.4,5 Previously, serum TNC level was reported to be
related to disease progression and to have prognostic significance
in DCM. Serum measurement of TNC level, because of its less
invasive nature, could serve as a potential clinical biomarker
reflecting TNC expression.19,20,22 In the present study, by directly .
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.. staining myocardial biopsy specimens, we demonstrated that high
TNC expression was related to a worse outcome and lower
occurrence of reverse remodelling in patients with DCM. As TNC
is not exclusively synthesized in the heart, but also in organs such
as the liver and lungs,3 direct histological investigation of myocar-
dial expression using a specific antibody appears to have great
significance.
Tenascin-C has several functions that weaken cell adhesion,
upregulate the expression and activity of matrix metallopro-
teinases, modulate inflammatory response, promote recruitment
of myofibroblasts, and enhance fibrosis.3 In an experimental
myocardial infarction model using genetically altered mice, TNC
deficiency ameliorated collagen accumulation in the infarct border
area, resulting in improved post-myocardial infarction cardiac
function.6 Tenascin-C has the structural capability to bind and
interact with other cells. This large extracellular matrix glyco-
protein, consisting of EGF-like repeats, fibronectin III repeats,
and a fibrinogen-like domain, has several biological effects. The
antibody we used in the current study recognizes the EGF-like
domain and is suitable to measure total myocardial TNC level,
because the subsequent fibronectin III domain contains a splice
variant region that varies considerably in its expression form. The
EGF-like repeat domain interacts with the epidermal growth factor
receptor, and the fibronectin III-like repeat domain binds integrins
to promote adhesion and mediates cell activation via toll-like
receptor 4, leading to sustained inflammation.23 The unfavourable
effects of TNC on ventricular remodelling in DCM might result
from ongoing myocardial damage or inability to repair the failing
heart because of sustained inflammation. There is increasing
evidence that splicing variants of TNC, especially those containing
the fibronectin III B or C domain, may influence tissue remodelling
in heart failure. Serum level, as well as cardiac tissue deposition,
of the B+ TNC variant was associated with mortality in DCM.22 In
patients with heart failure, serum levels of B+ and C+ TNC were
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Univariable and multivariable linear regression analysis of tenascin-C (TNC) area
Univariable Multivariable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
𝜷-coefficient P-value 𝜷-coefficient P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age −0.067 0.462 – –
Male −0.010 0.911 – –
Body mass index −0.016 0.862 – –
Current smoker −0.150 0.097 – –
NYHA III/VI 0.129 0.156 – –
Duration of heart failure 0.266 0.003 0.117 0.239
Systolic blood pressure −0.088 0.335 – –
Diastolic blood pressure −0.083 0.361 – –
Heart rate −0.017 0.850 – –
Hypertension 0.013 0.888 – –
Diabetes mellitus 0.266 0.003 0.199 0.034
Dyslipidaemia 0.008 0.931 – –
Atrial fibrillation 0.258 0.004 0.174 0.063
Left bundle branch block 0.117 0.198 – –
ICD/BiV-ICD 0.192 0.033 0.211 0.015
Log BNP 0.267 0.003 −0.040 0.735
HbA1c 0.055 0.556 – –
Haemoglobin −0.018 0.847 – –
eGFR −0.155 0.087 – –
Serum sodium −0.142 0.118 – –
𝛽-blocker on admission 0.146 0.108 – –
ACE inhibitor/ARB on admission 0.069 0.447 – –
Loop diuretic on admission 0.138 0.129 – –
Aldosterone inhibitor on admission 0.185 0.041 −0.072 0.444
Sulphonylurea on admission −0.062 0.492 – –
Glinide on admission −0.053 0.564 – –
Insulin on admission 0.031 0.737 – –
𝛽-blocker at discharge 0.104 0.253 – –
ACE inhibitor/ARB at discharge 0.090 0.320 – –
Loop diuretic at discharge 0.181 0.045 0.180 0.050
Aldosterone inhibitor at discharge 0.134 0.140 – –
Sulphonylurea at discharge −0.062 0.492 – –
Glinide at discharge 0.143 0.115 – –
Insulin at discharge −0.013 0.887 – –
LVEDD 0.017 0.852 – –
LVESD 0.004 0.961 – –
LVEF −0.195 0.089 – –
RVD 0.100 0.278 – –
Mitral regurgitation 0.018 0.841 – –
Restrictive filling pattern 0.215 0.017 0.099 0.270
Mean PCWP 0.254 0.005 −0.503 0.032
Mean PA 0.288 0.001 0.644 0.008
Cardiac index −0.206 0.026 0.013 0.890
Heart failure risk score 0.216 0.017 0.162 0.093
Collagen area 0.329 <0.001 0.128 0.209
TNC, tenascin-C; NYHA, New York Heart Association; ICD, implantable cardioverter defibrillator; BiV-ICD, biventricular implantable cardioverter defibrillator; BNP, brain
natriuretic peptide; HbA1C, haemoglobin A1c; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; LVEDD,
left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; RVD, right ventricular
diameter; PCWP, pulmonary capillary wedge pressure; PA, pulmonary artery pressure.
associated with heart chamber dilatation, physical performance,
and BNP level, suggesting that they are possible biomarkers for
disease severity.24 Further immunohistochemical analysis for TNC
splicing variants might provide additional valuable information
related to LV remodelling. .
..
..
..
..
..
..
. Another intriguing finding of this study was the relevance of dia-
betes mellitus to myocardial TNC. Multivariable analysis showed
that the presence of diabetes, as well as indices representing heart
failure severity such as previous implantation of ICD or biventricu-
lar ICD, mean PCWP, and mean PA, was independently associated
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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with myocardial TNC expression. Diabetic cardiomyopathy is a
disorder of heart muscle resulting from diabetes, the pathogen-
esis of which is yet to be clearly defined. Remodelling of cardiac
extracellular matrix is known to be a key pathological feature
of diabetic cardiomyopathy. Production of matricellular proteins
is increased by hyperglycaemia- and hyperinsulinaemia-induced
chronic inflammation, purportedly through transforming growth
factor-𝛽 signalling.25 In addition, persistent hyperglycaemia induces
the formation of advanced glycation end-products, which is associ-
ated with increased production and reduced turnover of matricel-
lular proteins.26 Taking into consideration that TNC is likely to be
upregulated in an inflammatory microenvironment, the increased
myocardial expression of TNC in the present study might have
been caused by stimulation of increased transforming growth
factor-𝛽 associated with diabetes mellitus. We believe that this
study also supports the pathophysiological significance of TNC
in diabetic cardiomyopathy, in that TNC may contribute to the
development of worsening heart function in diabetic patients. Fur-
thermore, from a clinical aspect, it is suggested that prevent-
ing or adequately controlling diabetes mellitus might be able to
reduce myocardial chronic inflammation, diminish myocardial TNC
expression and consequently promote cardiac reverse remodelling
in DCM patients.
In the present study, RV endomyocardial biopsy was selected to
collect myocardial tissue samples, in order to minimize the proce-
dural risk. It is controversial as to whether RV biopsy specimens
are adequate for evaluation of LV remodelling in cardiomyopathy.
We consider myocardial TNC measurement using RV myocardial
samples is reasonable for the present study for two reasons. First,
samples were obtained from the interventricular septum, which is
considered common to the right ventricle and left ventricle. Sec-
ond, progression of cardiac remodelling in DCM typically results in
both RV and LV dysfunction at the same time. In fact, there is evi-
dence that right ventricular dysfunction is correlated with LV dys-
function in patients with DCM.27 We experienced difficulty in RV
volumetric and functional assessment because of geometric com-
plexity and asymmetry of the RV.28 Cardiac magnetic resonance
imaging might be an option to evaluate RV remodelling.
There are several limitations to this study. First, this was a retro-
spective study that included a relatively small number of patients.
Follow-up echocardiography was not performed in all patients,
although 76% of the study population did undergo this procedure.
Larger prospective studies with complete follow-up are needed to
establish evidence for myocardial TNC expression in patients with
DCM. Second, endomyocardial biopsy specimens may have some
sampling errors. We used a transcatheter method to collect biopsy
samples from three to five different sites in the RV septum. Evalu-
ation of TNC accumulation was performed on all pieces collected,
thus mitigating sampling error. However, there are advantages to
evaluating myocardial deposition of the extracellular matrix by
direct collection of myocardium by endomyocardial biopsy. Third,
immunohistochemical analysis based on the use of an image pro-
cessing program would be able to provide semiquantitative results
at best. Future quantitative evaluation of myocardial TNC protein
or mRNA would strengthen our findings. Finally, the present study,
through focusing on accumulation of myocardial TNC expression, ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. could not completely clarify the mechanisms of LV remodelling
and worse outcome in DCM. Other histological approaches, for
example, evaluation of expression pattern or structure of TNC
are worth considering in future.
In conclusion, we have shown that myocardial TNC expression
was associated with lower occurrence of LV reverse remodelling
and poor long-term outcome in patients with DCM.
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